SK bioscience

본문바로가기

KOR ENG

sitemap

PR

SK bioscience company news updates

Press releases

SK bioscience Submits Emergency Use Listing (EUL) of SKYCovione™ to the World Health Organization

2022.09.08
SK bioscience Begins First Shipment of Korean COVID-19 Vaccine

2022.09.02
SK-Bill & Melinda Gates Foundation met to discuss shared commitments to global health

2022.08.16
SK bioscience Announces Adolescent Authorization of Protein Based COVID-19 Vaccine, Nuvaxovid

2022.08.12
SK bioscience Submits Application for Conditional Marketing Authorization of COVID-19 Vaccine, SKYCovion™ to European Medicines Agency

2022.08.01
SK bioscience Submits Conditional Marketing Authorization Application of COVID-19 Vaccine, SKYCovion™ to the Medicines and Healthcare Products Regulatory Agency

2022.07.29
SK bioscience Announces Agreement with Novavax to Manufacture COVID-19 Vaccine Containing Omicron Variant

2022.07.19
SK bioscience’s COVID-19 Vaccine ‘SKYCovione™’ Shows Cross-Neutralizing Activity Against Omicron Variant BA.1 as Booster Shot

2022.07.13
SK bioscience and GSK Announce Biologics License Application Approval of SKYCovione™ in Republic of Korea

2022.06.29
SK bioscience Marks Successful Completion of Global Forum to Prepare the Next Pandemic

2022.06.28